Walking with aid at 4 weeks · patients with Guillain‐Barré syndrome
Plasma exchange probably leads to higher walking with aid at 4 weeks compared with sham exchange or supportive treatment (moderate certainty).
1 finding from 1 review
Dependency on a ventilator at 4 weeks · patients with Guillain‐Barré syndrome
Plasma exchange probably leads to lower dependency on a ventilator at 4 weeks compared with sham exchange or supportive treatment (moderate certainty).
1 finding from 1 review
Full muscle strength recovery at 1 year · patients with Guillain‐Barré syndrome
Plasma exchange probably leads to higher full muscle strength recovery at 1 year compared with sham exchange or supportive treatment (moderate certainty).
1 finding from 1 review
Recurrence of hyperthyroidism (relapse) [measured by serum thyroid hormone levels above the normal range after withdrawal of methimazole or end of radioiodine treatment] · patients with Guillain‐Barré syndrome
Plasma exchange probably leads to higher relapses at 1 year compared with sham exchange or supportive treatment (moderate certainty).
1 finding from 1 review
Deaths at 1 year · patients with Guillain‐Barré syndrome
Plasma exchange showed no clear difference in deaths at 1 year compared with sham exchange or supportive treatment (high certainty).
1 finding from 1 review
Severe infection · patients with Guillain‐Barré syndrome
Plasma exchange showed no clear difference in severe infection compared with sham exchange or supportive treatment (moderate certainty).
1 finding from 1 review
1Trials were not blinded. · patients with Guillain‐Barré syndrome
1 finding from 1 review
no estimate extracted
1 participants
GRADE not reported
Change in disability after 4 weeks disability grade change. Scale from: 0 to 10. · people with CIDP
1 finding from 1 review
Change in impairment (NIS) after 4 weeks NIS score points. Scale from: 0 to 280; lower is better · people with CIDP
1 finding from 1 review
Change in mean compound muscle action potential amplitude after 4 weeks mA. Scale from: 0 to 10. · people with CIDP
1 finding from 1 review
Serious adverse events ‐ not measured · people with CIDP
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Only 1 trial. · people with CIDP
1 finding from 1 review
no estimate extracted
1 study · 1 participants
GRADE not reported
Change in disability Neuropathy Disability Score · people with IgG and IgA paraproteinaemic neuropathy
1 finding from 1 review
Change in sensation using a validated scale (e.g. INCAT sensory sum score) ‐ not measured · people with IgG and IgA paraproteinaemic neuropathy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in strength Neuropathy Disability Score (weakness) · people with IgG and IgA paraproteinaemic neuropathy
1 finding from 1 review
Adverse events ‐ not reported · people with IgG and IgA paraproteinaemic neuropathy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found